Loading Events

When

Tuesday, 30 Aug at 1:00 pm

Where

Zoom

Price

BOOK TICKETS
Join us for a fascinating presentation about CSIRO’s work developing innovative polymers for use in biomedical 3D printing!

Despite the significate interest in 3D printing, there still remains a need for 3D printing resins with a wider range of properties to enable the printing of functional parts to suit end-use applications rather than just prototypes. 3D printing is particularly attractive to the medical device industry were it potentially enables the rapid and cost-effective fabrication of patient specific devices. The fabrication of soft and elastic parts by 3D printing is challenging as soft materials are prone to plastic deformation during the 3D printing process. For instance, 3D printing of silicones (polysiloxanes) is very difficult to achieve, although there is market need to have silicone parts prototyped and customized in patient-specific devices fabricated. Moreover, the resultant 3D elastomeric object may not have sufficient mechanical properties for functional use.

Dr Hughes will discuss research at CSIRO on the development of new photocurable resins 3D printing designed to meet the needs of the polymer 3D printing industry, particularly for biomedical applications. The translation of simple photocure chemistry to a DLP printer is not as straight forwards as expected. There are many factors which need to be considered when developing resins for DLP printers, namely: formulation stability, cure time for each layer, plastic deformation, successful initiation of crosslinking reactions, and inhibition of unwanted curing.

Dr Timothy Hughes is a research team leader (Biomedical Polymers) at CSIRO, Australia. His research interests include the design and synthesis of polymers for biomedical applications. Particularly in the areas of drug delivery systems, ophthalmic devices, and resins for 3D printing. He led a polymer team to develop the microporous perfluoropolyether implants for correcting refractive error and polysiloxane macromonomers that can be used as injectable in situ curable accommodating intraocular lenses. Both technologies were licenced to a spin out company, Adventus Technologies Inc. More recently, Hughes has worked with a variety of companies developing drug delivery systems, photocurable sealants and resins for 3D printing. Dr Hughes has published more than 60 papers and is an inventor on 20 patent families. In addition, he has been co-awarded CSIRO Research Achievement Awards in 2009 and 2012 as well as the 2004 Royal Society Award for Interdisciplinary Research (Eureka Award)

Location:

Online